DEF: OptimizeRx Sets Annual Meeting Agenda, Proposes Equity Plan Changes

OptimizeRx Corporation has issued its proxy statement detailing the agenda for its upcoming Annual Meeting of Shareholders on June 9, 2026, including proposals to amend its 2021 Equity Incentive Plan.

Summary

• OptimizeRx Corporation is holding its Annual Meeting of Shareholders on June 9, 2026, entirely as a virtual webcast.
• Key agenda items include the election of seven directors, an advisory vote on executive compensation, and proposals to amend the 2021 Equity Incentive Plan.
• The proposed amendments to the 2021 Equity Plan include increasing the number of available shares by 1,000,000 and adopting an 'evergreen' provision for automatic annual increases.
• Shareholders will also vote on ratifying Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The company is seeking shareholder approval for these equity plan amendments to continue attracting, motivating, and retaining key personnel and to align executive compensation with shareholder interests.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting standard corporate governance and compensation practices, with a slight caution due to the low Say-on-Pay vote result and the potential for equity dilution.

Positives

• The company is proactively seeking shareholder approval for equity incentive plan amendments to support talent retention and motivation.
• The proposed amendments aim to align executive and employee interests with long-term shareholder value creation.
• The company is engaging with shareholders on executive compensation matters, as evidenced by outreach following the 2025 Say-on-Pay vote.
• A majority of director nominees are independent, indicating a commitment to strong corporate governance.
• The company has implemented stock ownership guidelines for directors and executive officers to further align interests.

Negatives

• The 2025 Say-on-Pay vote received a low level of support (58.53%), indicating shareholder concerns about executive compensation.
• The company is seeking to increase the number of shares available under its equity incentive plan, which could lead to dilution.
• There was a change in independent auditors, with UHY LLP being dismissed and Grant Thornton LLP appointed.
• A material weakness in internal control over financial reporting related to data from third-party service organizations was identified in prior years and discussed with UHY.

Risks

• Failure to approve the equity plan amendments could compel the company to increase cash compensation, potentially not aligning with shareholder interests and increasing cash expenses.
• The proposed increase in equity awards could lead to dilution for existing shareholders.
• The company's forward-looking statements are subject to risks and uncertainties, as detailed in its Form 10-K and subsequent filings.
• The company previously identified a material weakness in internal control over financial reporting, although it did not result in restatements or disagreements with the prior auditor.

Future Outlook

The company is seeking shareholder approval for amendments to its 2021 Equity Incentive Plan to ensure sufficient shares are available for future awards, which are considered critical for attracting, motivating, and retaining talent. The proposed increase of 1,000,000 shares is expected to cover awards for approximately one year, and the evergreen provision aims to provide ongoing flexibility.

Management Comments

• "Equity-based compensation awards are a critical element of our overall compensation program. We believe that our long-term incentive compensation program aligns the interests of management, employees, and the shareholders to create long-term shareholder value."
• "If the amendment to the 2021 Equity Plan is not approved, we may be compelled to increase significantly the cash component of our employee and director compensation, which approach may not necessarily align employee and director compensation interests with the investment interests of our shareholders."
• "We believe that the additional 1,000,000 shares will provide sufficient authorized shares available under the 2021 Equity Plan for the grant of awards for approximately one year."
• "The automatic increase in the number of shares of Common Stock available under the 2021 Equity Plan each year will save the Company the time and expense which would otherwise be required to prepare and file a proxy statement and solicit shareholder votes in order to increase the share pool."

Industry Context

StockSavvy.ai notes that OptimizeRx's proposals to increase equity awards and implement an evergreen provision are common strategies in the health tech and software sectors to remain competitive in attracting and retaining talent, especially in a market where equity-based compensation is a key differentiator.

Comparison to Industry Standards

• The proposed increase of 1,000,000 shares represents 5.3% of outstanding shares as of April 10, 2026. This level of potential dilution is within typical ranges for companies in the health technology sector seeking to fund equity compensation.
• The 'evergreen' provision, proposing a 5% annual increase in shares, is a mechanism seen in some technology companies to automatically replenish equity pools, though the specific duration (five years) and percentage are company-specific.
• The company's burn rate for equity awards in 2025 was 6.6%, which is moderate compared to some high-growth technology companies but requires careful monitoring to avoid excessive dilution.
• The compensation committee's use of a peer group for benchmarking executive pay, including companies like American Well, Health Catalyst, and Phreesia, aligns with industry practices for health tech and software firms.

Corporate Governance

Related Party Transactions

• OptimizeRx has a Reseller Agreement with EVERSANA Life Science Services, LLC, where James Lang (a Board Member) is on the Board of Directors. EVERSANA may offer OptimizeRx solutions to its customers. Revenue generated from this agreement was $922,416 in 2025 and $375,280 in 2024. These opportunities were reviewed and approved by the Audit Committee and deemed to be at market rates and in the normal course of business.

Stakeholder Impact

• Shareholders: Voting on director elections, executive compensation, and equity plan amendments directly impacts shareholder rights and potential dilution. The Say-on-Pay vote result indicates potential shareholder dissatisfaction with current compensation practices.
• Employees: The proposed equity plan amendments are intended to attract, motivate, and retain employees, including executive officers, by providing long-term incentives.
• Management: Executive compensation is a key focus, with proposals to amend equity plans and an advisory vote on current compensation levels.
• Auditors: A change in independent auditors from UHY LLP to Grant Thornton LLP will impact the audit process for the upcoming fiscal year.

Next Steps

• Shareholders will vote on the proposed agenda items at the Annual Meeting on June 9, 2026.
• If approved, the amendments to the 2021 Equity Incentive Plan will be implemented.
• Grant Thornton LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2026, subject to ratification.

Key Dates

Recommendation

The filing outlines standard annual meeting proposals, including director elections and equity plan amendments, which are typical for a public company. While the company is seeking to enhance its equity incentive program, the previous low support for the Say-on-Pay vote and the potential for dilution warrant a 'hold' recommendation pending further clarity on shareholder sentiment and the impact of the proposed equity increases.

Keywords

OptimizeRx, Proxy Statement, Annual Meeting, Equity Incentive Plan, Director Election, Executive Compensation, Shareholder Vote, Grant Thornton LLP, Corporate Governance, Stock Options, Restricted Stock Units